PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Tenofovir Disoproxil→

Tenofovir Disoproxil PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
201341-05-1
Molecular formula
C19H30N5O10P
Molecular weight
519.4 g/mol
Drug class
Acyclic nucleotide phosphonate prodrugantiretroviral reverse-transcriptase inhibitor precursor
Mechanism of action
Tenofovir disoproxil is a prodrug that is hydrolysed to tenofovir and subsequently phosphorylated intracellularly to tenofovir diphosphate. Tenofovir diphosphate competitively inhibits HIV reverse transcriptase and HBV DNA polymerase and causes DNA-chain termination. Fumarate is the salt component; the disoproxil moiety is the prodrug.
Indications / reported uses
  • Treatment of HIV-1 infection in combination with other antiretroviral agents
  • Treatment of chronic hepatitis B in adults and adolescents where authorised; use requires current product-specific eligibility, renal assessment and monitoring

Sources: US DailyMed — Tenofovir disoproxil fumarate · EMA — Viread · NIH HIV drug information — Tenofovir disoproxil fumarate

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Tenofovir Disoproxil PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Tenofovir Disoproxil Permitted Daily Exposure (PDE) report (the Tenofovir Disoproxil PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Tenofovir Disoproxil Occupational Exposure Limit (OEL) report (the Tenofovir Disoproxil OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.